Koyfin Home > Directory > Health Care > Horizon Therapeutics > EBITDA / Interest Expenses

Horizon Therapeutics EBITDA / Interest Expenses Chart (HZNP)

Horizon Therapeutics annual/quarterly EBITDA / Interest Expenses from 2010 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Horizon Therapeutics EBITDA / Interest Expenses for the quarter ending September 09, 2020 was $19m a 82.32% increase of 16m year over year
  • Horizon Therapeutics EBITDA / Interest Expenses for the last 12 months ending September 09, 2020 was $5m a 66.00% increase of 3m year over year
  • Horizon Therapeutics Annual EBITDA / Interest Expenses for 2019 was $2m a 66.86% increase of 1m from 2018
  • Horizon Therapeutics Annual EBITDA / Interest Expenses for 2018 was $1m a 144.17% increase of 1m from 2017
  • Horizon Therapeutics Annual EBITDA / Interest Expenses for 2017 was $0m a 103.91% decrease of 0m from 2016
Other Ratios Metrics:
  • Horizon Therapeutics Total Debt / Capital for the quarter ending December 12, 2018 was $64m a -7.15% decrease of -5m year over year
  • Horizon Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $434m a -18.99% decrease of -82m year over year
  • Horizon Therapeutics Total Debt / Equity for the quarter ending December 12, 2018 was $180m a -22.96% decrease of -41m year over year
View Chart On Koyfin

Quarterly HZNP EBITDA / Interest Expenses Data

09/2020$19m
06/2020$3m
03/2020$0m
12/2019$3m
09/2019$3m
06/2019$2m
03/2019$0m
12/2018$2m
09/2018$2m
06/2018$1m

Annual HZNP EBITDA / Interest Expenses Data

2019$2m
2018$1m
2017$0m
2016$0m
2015$1m
2014$0m
2013$-3m
2012$-7m
2011$-8m
2010$-14m